Previous Close | 3.1600 |
Open | 3.3000 |
Bid | 3.1000 x 1000 |
Ask | 3.3500 x 3100 |
Day's Range | 3.1657 - 3.3000 |
52 Week Range | 1.8000 - 4.8300 |
Volume | |
Avg. Volume | 13,886 |
Market Cap | 19.103M |
Beta (5Y Monthly) | 1.19 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9170 |
Earnings Date | Jul 14, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.00 |
Lexaria Bioscience: Charting a Path to Commercial Success
/ Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that the former President of GW Pharmaceuticals USA, Julian Gangolli, is joining Lexaria Bioscience Corp as a Strategic Advisor.
By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT January 2023 Operational Update Lexaria Bioscience Corporation’s (NASDAQ:LEXX) CEO, Chris Bunka, published a shareholder letter last week highlighting 2022 achievements and outlining the expected path forward for its portfolio of programs. Mr. Bunka listed capital expenditure priorities, summarized successful results from